Wednesday, 17 April, 2024
HomeMedico-LegalJudge sceptical about Bayer settlement of Roundup claims

Judge sceptical about Bayer settlement of Roundup claims

Bayer AG shares have slumped after a US judge questioned part of the company's recent multibillion-dollar settlement over its glyphosate-based weed killer Roundup, reports Morning Star. Californian Judge Vince Chhabria, who is responsible for settling future damages claims, expressed concern about the appropriateness of the settlement that the German chemical company agreed to in late June.

“The court is sceptical of the propriety and fairness of the proposed settlement, and is tentatively inclined to deny the motion,” the judge said. Bayer has been hounded by the glyposate-based product since it took over US agrichemicals company Monsanto in 2018, an acquisition that included Roundup and thousands of related lawsuits.

The report says uncertainty over how the litigation issue would be resolved was alleviated in late June when the company struck a $10.9bn settlement deal in the US. As part of the settlement, it was agreed that for potential future cases a scientific panel would decide whether Bayer's product actually causes non-Hodgkin's lymphoma.

However, Chhabria expressed doubts as to whether it was right to take this question out of the courts and delegate it to scientists, among other issues. Bayer said it appreciates the judge raising his preliminary concerns.

“We take (this) seriously and will address at the preliminary approval hearing on 24 July,” the company is quoted in the report as saying.

[link url="https://www.morningstar.com/news/dow-jones/202007073169/bayer-shares-slump-after-judge-questions-settlement"]Full Morning Star report[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.